



NEWS RELEASE

FOR IMMEDIATE RELEASE

Contact:

Sheryl Seapy, Pure Communications
(949) 608-0841

XDx Appoints New Chief Financial Officer

BRISBANE, CA, January 5, 2010 – XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests for the monitoring of immune-mediated conditions, today announced that it has appointed Jean-Frederic Viret, Ph.D. as its chief financial officer.

“We are pleased to welcome Dr. Viret to XDx and we believe that his experience at publicly-traded and privately-held companies will allow him to be immediately additive to our team,” stated Pierre Cassigneul, president and chief executive officer of XDx. “With a number of upcoming strategic milestones including major announcements stemming from our IMAGE study for AlloMap HTx and significant improvements to our financial model, we expect 2010 to be a very exciting year for XDx. Jean has wide-ranging expertise in several aspects of financial management including private and public financings, M&A-related accounting activities and strategic business development collaboration. His strong financial management and capital markets expertise will be valuable as we continue to build our leadership in molecular diagnostics.”

Prior to joining XDx, Dr. Viret was the chief financial officer at Anesiva, Inc., a publicly traded specialty pharmaceutical company, a position he assumed following several years of roles of escalating responsibility. While at Anesiva, he worked on teams that successfully raised more than \$200 million in public and private financings, including the company’s IPO. Prior to Anesiva, Dr. Viret was the associate director of finance at Tularik, a therapeutics company focused on cancer, immunology and metabolic diseases that was acquired by Amgen in 2004. Dr. Viret began his career in finance at PricewaterhouseCoopers LLP, where he worked in the biotech, high-tech and venture capital groups. He completed a postdoctoral fellowship in molecular biology at the Massachusetts Institute of Technology and was a visiting fellow in molecular biology at Harvard University.

Dr. Viret is a certified public accountant (inactive) and board member of the Association of Biotech Financial Officers. He received a Ph.D. in molecular biology from Université Louis Pasteur and an M.B.A. from Cornell University.

About XDx

Based in Brisbane, California, XDx is a molecular diagnostics company focused on the discovery, development and commercialization of noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed a proprietary testing, the AlloMap® Molecular Expression Testing, which provides transplant physicians with a new tool to aid in the determination of the probability of acute cellular rejection for post-cardiac transplant patient management.

Some of the AlloMap Molecular Expression Technology developed and implemented by XDx in heart transplant patient management may be applicable to other conditions that involve transplant rejection and diseases that affect the immune system. XDx's noninvasive technology offers the potential to decrease healthcare costs and significantly improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases.

XDx has several ongoing studies focused on FDA-approved AlloMap Molecular Expression Testing. The company anticipates results from its Invasive Monitoring Attenuation through Gene Expression (IMAGE) trial, a comparative efficacy clinical study designed to demonstrate the non-inferiority of clinical outcomes of heart transplant recipients managed with the AlloMap test compared to endomyocardial biopsy, in early 2010.

###